Biogen wins in Tecfidera patent case; share price goes up.

From Barron's on Wednesday, 5 Feb. 2020 :


Shares of the biotech firm Biogen jumped more than 23% midday Wednesday [Feb. 5]
after the company won a long-awaited decision in a patent case defending its
multiple sclerosis drug Tecfidera against a challenge by Mylan.




link: https://www.barrons.com/articles/biogen-stock-major-patent-win-51580929944

IPR2018-01403 on US 8,399,514

See also:
http://www.biopharmalaw.com/blog/category/ipr : Biogen's Multiple Sclerosis Drug, Tecfidera, Faces Another IPR Threat

https://developer.uspto.gov/ptab-web/#/search/decisions